The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Development of the Proteasome Inhibitor PS-341
Open accessAbstract
Over the last decade, the critical role of the proteasome in cell-cycle regulation has become increasingly apparent. The proteasome, a multicatalytic protease present in all eukaryotic cells, is the primary component of the protein degradation pathway of the cell. By degrading regulatory proteins (or their inhibitors), the proteasome serves as a central conduit for many cellular regulatory signals and, thus, is a novel target for therapeutic drugs. PS-341 is a small molecule that is a potent and selective inhibitor of the proteasome. In vitro and mouse xenograft studies of PS-341 have shown antitumor activity in a variety of tumor types, including myeloma, chronic lymphocytic leukemia, prostate cancer, pancreatic cancer, and colon cancer, among others. Although PS-341 rapidly leaves the vascular compartment, a novel pharmacodynamic assay has shown that inhibition of proteasome—the biologic target—is dose dependent and reversible. These studies provided the rationale for a twice-weekly dosing schedule employed in ongoing clinical studies. Phase I trials in a variety of tumor types have shown PS-341 to be well tolerated, and phase II trials in several hematologic malignancies and solid tumor types are now in progress. Efficacy and safety data from the most advanced of these, a phase II multicenter trial in myeloma, will be available in early 2002.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wang, C.-Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V., & Baldwin, A. S. (1998) · Science · doi:10.1126/science.281.5383.1680 · Cited by 2,711
Structure of 20S proteasome from yeast at 2.4Å resolution
Groll, M., Ditzel, L., Löwe, J., Stock, D., Bochtler, M., Bartunik, H. D., & Huber, R. (1997) · Nature · doi:10.1038/386463a0 · Cited by 2,257
Pagano, M., Tam, S. W., Theodoras, A. M., Beer-Romero, P., Del Sal, G., Chau, V., Yew, P. R., Draetta, G. F., & Rolfe, M. (1995) · Science · doi:10.1126/science.7624798 · Cited by 1,817
Crystal Structure of the 20 S Proteasome from the Archaeon T. acidophilum at 3.4 Å Resolution
Löwe, J., Stock, D., Jap, B., Zwickl, P., Baumeister, W., & Huber, R. (1995) · Science · doi:10.1126/science.7725097 · Cited by 1,525
Hideshima, T., Richardson, P. G. G., Chauhan, D., Palombella, V. J., Elliott, P. J., Adams, J., & Anderson, K. C. (2001) · PubMed · Cited by 1,508
Self-citationProteasome inhibitors: a novel class of potent and effective antitumor agents.
Adams, J., Palombella, V. J., Sausville, E. A., Johnson, J. I., Destree, A. T., Lazarus, D. D., Maas, J., Pien, C. S., Prakash, S., & Elliott, P. J. (1999) · PubMed · Cited by 1,477
Self-citationDulić, V., Kaufmann, W. K., Wilson, S. J., Tisty, T. D., Lees, E., Harper, J. W., Elledge, S. J., & Reed, S. I. (1994) · Cell · doi:10.1016/0092-8674(94)90379-4 · Cited by 1,465 · cited 1×
“proteasome pathway (Table 1), and inhibiting their requisite degradation has been clearly implicated in sensitizing cells to apoptosis [ 16-18 ].”
BackgroundControl of oncogenesis and cancer therapy resistance by the transcription factor NF-κB
Baldwin, A. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11991 · Cited by 1,434
Chen, Z., Hagler, J., Palombella, V. J., Melandri, F., Scherer, D., Ballard, D., & Maniatis, T. (1995) · Genes & Development · doi:10.1101/gad.9.13.1586 · Cited by 1,290
How Proteolysis Drives the Cell Cycle
King, R. W., Deshaies, R. J., Peters, J.-M., & Kirschner, M. W. (1996) · Science · doi:10.1126/science.274.5293.1652 · Cited by 1,273
Winston, J. T., Strack, P., Beer-Romero, P., Chu, C. Y., Elledge, S. J., & Harper, J. W. (1999) · Genes & Development · doi:10.1101/gad.13.3.270 · Cited by 954
The Rel/NF-κB Family Directly Activates Expression of the Apoptosis Inhibitor Bcl-x L
Chen, C., Edelstein, L. C., & Gélinas, C. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.8.2687-2695.2000 · Cited by 760
Zong, W.-X., Edelstein, L. C., Chen, C., Bash, J., & Gelinas, C. (1999) · Genes & Development · doi:10.1101/gad.13.4.382 · Cited by 720
Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-alpha.
Brown, K., Park, S., Kanno, T., Franzoso, G., & Siebenlist, U. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.6.2532 · Cited by 621
Wang, C.-Y., Guttridge, D. C., Mayo, M. W., & Baldwin, A. S. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.9.5923 · Cited by 590
Signal-induced degradation of I kappa B alpha requires site-specific ubiquitination.
Scherer, D. C., Brockman, J. A., Chen, Z., Maniatis, T., & Ballard, D. W. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.24.11259 · Cited by 554
Houston, M. A., Abendroth, K., Baldwin, A. S., & Liu, R. (2001) · PubMed · doi:10.17615/k359-fr77 · Cited by 547
Activation of the cell death program by inhibition of proteasome function
Drexler, H. C. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.3.855 · Cited by 481
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.
Aghajanian, C. A., Soignet, S. L., Dizon, D. S., Pien, C. S., Adams, J., Elliott, P. J., Sabbatini, P. J., Miller, V. A., Hensley, M. L., Pezzulli, S., et al. (2002) · PubMed · Cited by 447
Self-citationAlkalay, I., Yaron, A., Hatzubai, A., Orian, A., Ciechanover, A., & Ben-Neriah, Y. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.23.10599 · Cited by 440
Signal-induced ubiquitination of Ikappa Balpha by the F-box protein Slimb/beta -TrCP
Spencer, E., Jiang, J., & Chen, Z. J. (1999) · Genes & Development · doi:10.1101/gad.13.3.284 · Cited by 431
An, B., Goldfarb, R. H., Siman, R., & Dou, Q. P. (1998) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400436 · Cited by 337
Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-κB
Russo, S. M., Tepper, J. E., Baldwin, A. S., Liu, R., Adams, J., Elliott, P., & Cusack, J. C. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01446-8 · Cited by 318
Self-citationCleavage motifs of the yeast 20S proteasome β subunits deduced from digests of enolase 1
Nussbaum, A. K., Dick, T. P., Keilholz, W., Schirle, M., Stevanović, S., Dietz, K., Heinemeyer, W., Groll, M., Wolf, D. H., Huber, R., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.21.12504 · Cited by 311
Proteasome Inhibition Measurements: Clinical Application
Lightcap, E. S., McCormack, T. A., Pien, C. S., Chau, V., Adams, J., & Elliott, P. J. (2000) · Clinical Chemistry · doi:10.1093/clinchem/46.5.673 · Cited by 301
Self-citationPatel, N. M., Nozaki, S., Shortle, N. H., Bhat-Nakshatri, P., Newton, T. R., Rice, S., Gelfanov, V., Boswell, S. H., Goulet, R. J., Sledge, G. W., et al. (2000) · Oncogene · doi:10.1038/sj.onc.1203768 · Cited by 294
Ubiquitin-dependent Destruction of Topoisomerase I Is Stimulated by the Antitumor Drug Camptothecin
Desai, S. D., Liu, L. F., Vazquez-Abad, D., & D'Arpa, P. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.39.24159 · Cited by 269
Transcription factor NF-κB is constitutively activated in acute lymphoblastic leukemia cells
Kordes, U., Krappmann, D., Heissmeyer, V, Ludwig, W., & Scheidereit, C. (2000) · Leukemia · doi:10.1038/sj.leu.2401705 · Cited by 264
26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer
Shah, S. A., Potter, M. W., McDade, T. P., Ricciardi, R., Perugini, R. A., Elliott, P. J., Adams, J., & Callery, M. P. (2001) · Journal of Cellular Biochemistry · doi:10.1002/jcb.1150 · Cited by 260
Self-citationLin, Y. C., Brown, K., & Siebenlist, U. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.2.552 · Cited by 246
Chiarle, R., Budel, L. M., Skolnik, J., Frizzera, G., Chilosi, M., Corato, A., Pizzolo, G., Magidson, J., Montagnoli, A., Pagano, M., et al. (2000) · Blood · doi:10.1182/blood.v95.2.619 · Cited by 216
Role of I Bα Ubiquitination in Signal-induced Activation of NF- B in Vivo
Roff, M., Thompson, J., Rodriguez, M. S., Jacque, J.-M., Baleux, F., Arenzana-Seisdedos, F., & Hay, R. T. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.13.7844 · Cited by 214
Chemosensitization of Pancreatic Cancer by Inhibition of the 26S Proteasome
Bold, R. J., Virudachalam, S., & McConkey, D. J. (2001) · Journal of Surgical Research · doi:10.1006/jsre.2001.6194 · Cited by 212
An, W., Hwang, S.-G., Trepel, J., & Blagosklonny, M. (2000) · Leukemia · doi:10.1038/sj.leu.2401812 · Cited by 207
Critical Role for Lysines 21 and 22 in Signal-induced, Ubiquitin-mediated Proteolysis of IkB-α
Baldi, L., Brown, K., Franzoso, G., & Siebenlist, U. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.1.376 · Cited by 177
Masdehors, P., Ōmura, S., Merle‐Béral, H., Mentz, F., Cosset, J., Dumont, J., Magdelénat, H., & Delić, J. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01388.x · Cited by 159
New insights into role of microenvironment in multiple myeloma
Tricot, G. J. K. (2000) · The Lancet · doi:10.1016/s0140-6736(00)00019-2 · Cited by 149
NF- κ B and chemoresistance: potentiation of cancer drugs via inhibition of NF- κ B
Cusack, J. C., Liu, R., & Baldwin, A. S. (1999) · Drug Resistance Updates · doi:10.1054/drup.1999.0094 · Cited by 86
Dietrich, C., Bartsch, T., Schanz, F., Oesch, F., & Wieser, R. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.10815 · Cited by 77
The proteasome controls the expression of a proliferation-associated nuclear antigen Ki-67
Wu, Y., Luo, H., Kanaan, N., & Wu, J. (2000) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(20000315)76:4<596::aid-jcb8>3.0.co;2-n · Cited by 42
Cited by
Advances in Copper Complexes as Anticancer Agents
Santini, C., Pellei, M., Gandin, V., Porchia, M., Tisato, F., & Marzano, C. (2014) · Chemical Reviews · doi:10.1021/cr400135x · Cited by 1,790
Copper Complexes as Anticancer Agents
Marzano, C., Pellei, M., Tisato, F., & Santini, C. (2009) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152009787313837 · Cited by 802
The development of proteasome inhibitors as anticancer drugs
Adams, J. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00120-5 · Cited by 781
Self-citationDevelopment of the Proteasome Inhibitor Velcade™ (Bortezomib)
Adams, J., & Kauffman, M. (2004) · Cancer Investigation · doi:10.1081/cnv-120030218 · Cited by 654
Self-citationHelbig, G., Christopherson, K. W., Bhat-Nakshatri, P., Kumar, S., Kishimoto, H., Miller, K. D., Broxmeyer, H. E., & Nakshatri, H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300609200 · Cited by 639
Metadata
- Authors
- Adams, J.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-02-01
- Volume
- 7
- Issue
- 1
- Pages
- 9-16
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2169590701
- Cited by
- 369
- References
- 40
- FWCI
- 11.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.